Brussee, Helmut

Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial

Tomaschitz, A., Verheyen, N., Meinitzer, A., Pieske, B., Belyavskiy, E., Brussee, H., Haas, J., März, W., Pieske-Kraigher, E., Verheyen, S., et al. (2016) · Journal of Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 24

Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial

Verheyen, N., Fahrleitner-Pammer, A., Pieske, B., Meinitzer, A., Belyavskiy, E., Wetzel, J., Gaksch, M., Grübler, M. R., Catena, C., Sechi, L. A., et al. (2016) · Journal of Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 24

Plasma parathyroid hormone and cardiovascular disease in treatment‐naive patients with primary hyperparathyroidism: The EPATH trial

Wetzel, J., Pilz, S., Grübler, M. R., Fahrleitner‐Pammer, A., Dimai, H. P., von Lewinski, D., Kolesnik, E., Perl, S., Trummer, C., Schwetz, V., et al. (2017) · The Journal of Clinical Hypertension

Parathyroid Disorders and TreatmentsHormonal Regulation and Hypertension

Cited by 22